logo
  

Molson Coors Brewing Q2 Profit Increases - Quick Facts

Molson Coors Brewing Company (TAP, TPX.TO) reported that its second-quarter 2014 net income attributable to the company increased to $290.9 million from the prior year's $267.3 million, with earnings per share improving to $1.56 from $1.45 last year.

Underlying after-tax income per share grew to $1.57 from $1.47 in the prior year quarter.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.46 per share for the quarter. Analysts' estimates typically exclude special items.

Molson Coors Brewing reported a 7.9 percent increase in underlying after-tax income for the second quarter 2014, driven by improved performance from MillerCoors and Europe, along with lower interest expense versus a year ago. Worldwide beer volume decreased 0.9 percent, but net sales increased 0.9 percent in the second quarter of 2014.

Net sales for the quarter was $1.189 billion, up from $1.178 billion in the year ago quarter. Wall Street analysts had a consensus revenue estimate of $1.18 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT